Agenus (formerly Antigenics Inc.) was founded in 1994 by Garo H. Armen and Pramod K. Srivastava. The company has pioneered immunotherapies, including heat shock protein-based cancer vaccines, a program that has developed into its Prophage Series of personalized anti-cancer vaccines. Stock analysis for Agenus Inc (AGEN:NASDAQ CM) including stock price, stock chart, company news, key statistics, fundamentals and company profile. 01/11/2019 · Agenus Inc. company facts, information and stock details by MarketWatch. View agen business summary and other industry information. 23/08/2018 · Agenus' stock has been ripping higher this week, but that doesn't make it a strong buy. George Budwell (TMFGBudwell) Aug 23, 2018 at 10:00AM Author Bio. George Budwell has been writing about healthcare and biotechnology companies at the Motley Fool since 2013. His primary interests are novel small molecule drugs, next
11 Jul 2019 Agenus has been slogging the biotech byways since its 1994 count are adjusted for the one for six reverse stock split that Agenus endured in
01/03/2017 · agenus pipeline agenus inc stock agenus incyte agenus share price agenus glassdoor agenus west agenus annual report agenus acquisition agenus and incyte agenus adjuvant agenus after hours agenus acquired 4-antibody agenus and merck agenus antigenics agenus 4 antibody agenus inc agen agenus bio agenus buyout agenus berkeley ca agenus basel Agenus is leveraging the power of Computational Immuno-Oncology to fuel a new wave of innovative I-O therapies that address resistance pathways and have the potential to significantly improve treatment of patients with cancer. Agenus is leveraging this platform for … Agenus Commences Combination Trial of its Next-Gen CTLA-4 with its PD-1 Antibody December 19, 2019 Agenus to Host R&D Day November 15, 2019 November 12, 2019 Agenus receives $10M from UroGen Pharma for rights to Zalifrelimab (CTLA-4) for intravesical treatment … Agenus is an immuno-oncology company designed to deliver innovation with speed for patients with cancer. We have a unique portfolio of antibodies, vaccines, cell therapies (through our AgenTus Therapeutics subsidiary) and adjuvants designed to treat cancers with optimal combinations. NewsSee all news. 09 January 2020 Agenus Announces the Appointment of Dr. Jennifer Buell to the position of President and COO. LEXINGTON, Mass., Jan. 9, 2020 /PRNewswire/ -- Agenus Inc. (NASDAQ:AGEN), an immuno-oncology company with an extensive pipeline of agents that activate immune response to cancers, is pleased to announce the appointment
@JohnNosta RT @Agenus_Bio: $AGEN at #JPM20. On track to file 2 BLAs during 2020 and novel IO combinations in the clinic. https://t.co/M6obgqnxlH for…
Click to view the variety of blogs on Biotech and Pharmaceutical Companies covering different topics from Smith on Stocks.SmithOnStocks Mailbox January 28, 2014 | Expert Financial…https://smithonstocks.com/smithonstocks-mailbox-january-28-2014In my writing, I have found that there are some very smart people out there who have interesting questions and perspectives. I have decided to periodicallyUpdate on Currently Recommended Stocks of SmithOnStocks.com…https://smithonstocks.com/update-on-currently-recommended-stocks-of…Report Overview I periodically update my recommendations and that is the objective of this report. I also spend some time on my analytical approach andNasdaq Comp. Index Today | Compx LIVE Ticker | Nasdaq Comp.https://markets.businessinsider.com/nasdaq-compositeNasdaq Comp. Today: Get all information on the Nasdaq Comp. Index including historical chart, news and constituents. SpeculatingStocks is a discovery engine for stocks, blending stock data and social networking, listing many stocks for investors to find and discuss.